Catalent (CTLT) Tops Q1 EPS by 1c

Catalent (NYSE: CTLT) reported Q1 EPS of $0.16, $0.01 better than the analyst estimate of $0.15. Revenue for the quarter came in at $442.2 million versus the consensus estimate of $430.24 million.

GUIDANCE:

Catalent sees FY2017 revenue of $1.92-1.995 billion, versus the consensus of $1.95 billion.

"We're pleased to start fiscal year 2017 with strong revenue growth, the completion of a strategic acquisition, and several exciting developments on the Biologics front," said John Chiminski, President and Chief Executive Officer of Catalent, Inc. "The acquisition of Pharmatek adds extensive early-phase drug development capabilities from discovery to clinic and brings spray drying technology into Catalent’s extensive portfolio of advanced delivery technologies. The Biologics project wins this quarter highlight our differentiated technology platforms in this space in support of our customers and patients."

For earnings history and earnings-related data on Catalent (CTLT) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Cyngn Inc (CYN) CEO Issues Business Update
• Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss